A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT04990440
- Locations
- 🇦🇷
Conexa Investigacion Clinica S.A., Caba, Argentina
🇦🇷Clínica Adventista Belgrano, Caba, Argentina
🇦🇷CINME - Centro de Investigaciones Metabolicas, Ciudad de Buenos Aires, Argentina
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT04988308
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Forcare Clinical Research, Inc., Tampa, Florida, United States
🇺🇸Allcutis Research, Beverly, Massachusetts, United States
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 776
- Registration Number
- NCT04988295
- Locations
- 🇳🇱
VUMC Amsterdam, Amsterdam, Netherlands
🇲🇽Instituto Nacional de Cancerologia, Mexico, Mexico
🇲🇽Oncologia Integral Satelite, Naucalpan, Mexico
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04985955
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: JNJ-67484703Drug: Placebo
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT04985812
- Locations
- 🇭🇺
Clinexpert Kft, Gyöngyös, Hungary
🇭🇺Budai Irgalmasrendi Korhaz, Budapest, Hungary
🇭🇺CRU Hungary Kft., Kistarcsa, Hungary
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT04978337
- Locations
- 🇺🇸
Pines Care Research Center Inc, Pembroke Pines, Florida, United States
🇺🇸Renovatio Clinical, The Woodlands, Texas, United States
🇺🇸Frontier Clinical Research, Morgantown, West Virginia, United States
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04973566
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
- Conditions
- Sjogren's Syndrome
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04968912
- Locations
- 🇺🇸
St. Paul Rheumatology P A, Eagan, Minnesota, United States
🇪🇸Hosp Reina Sofia, Córdoba, Spain
🇪🇸Hosp Univ A Coruna, La Coruña, Spain
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
- Conditions
- Renal Impairment
- Interventions
- Drug: JNJ-73763989
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT04963738
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04960124
- Locations
- 🇩🇪
APEX GmbH, Munchen, Germany
🇩🇪CRS Clinical Research Services Kiel GmbH, Kiel, Germany